Medication info
Tugheonjon 10/16 mg

Tugheonjon 10/16 mg

Prescription medicationTabletOral
Ingredient · strength
Rosuvastatin Calcium›10.4mg / 1 tabletCandesartan Cilexetil›16mg / 1 tablet
Manufacturer / importer
Dong-A ST Co., Ltd.
Appearance
Yellow, round film-coated tablets
Packaging
30 tablets (10 tablets/PTP x 3)
Approval status
Active

MFDS item code 201702409 · Approved 2017.05.16 · Insurance code 642507420

Summary

Main use
Treatment of hypertension and heart failure, improvement of dyslipidemia, and suppression of the progression of atherosclerosis and cardiovascular risk
Who takes it
Adults · Children
Adult dose
This medicine is for use in adults only. The dose should be individualized for each patient based on the efficacy and tolerability of each component, candesartan cilexetil and rosuvastatin. ○ Candesartan cilexetil 1. Essential hypertension 1) Adults: The recommended initial and maintenance dose is 8 ∼ 16 mg of candesartan cilexetil orally once daily. If blood pressure is not adequately controlled after 4 weeks of treatment with 16 mg once daily, the dose may be increased to a maximum of 32 mg once daily. If blood pressure is still not controlled at this dose, other treatments should be considered. The maximum effect is achieved within 4 weeks of starting treatment. 2) Elderly patients: No adjustment of the initial dose is necessary. 3) Patients with intravascular volume depletion: For patients at increased risk of hypotension, such as those with volume depletion, administer an initial dose of 4 mg with careful monitoring. 4) Patients with renal impairment: The initial dose for patients with renal impairment, including those receiving hemodialysis, is 4 mg; adjust the dose according to the patient's response. Experience in patients with severe or end-stage renal impairment (creatinine clearance < 15 mL/min) is limited. 5) Patients with hepatic impairment: The initial dose for patients with mild to moderate hepatic impairment is 2 mg once daily; adjust the dose according to the patient's response. There is no experience in patients with severe hepatic impairment. 2. Heart failure 1) Adults: An initial dose of 4 mg once daily is recommended. The dose may be doubled at intervals of 2 weeks or more, up to a maximum of 32 mg once daily, depending on the patient's tolerability. 2) Elderly patients, patients with intravascular volume depletion, patients with renal impairment, and patients with mild to moderate hepatic impairment: No adjustment of the initial dose is necessary. ○ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, which controls the condition in most patients. The maintenance dose should be appropriately adjusted at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and the patient's response, and may be increased to a maximum of 20 milligrams daily. 2. Elderly patients: No dose adjustment is necessary. 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering this medicine at a dose of 20mg to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but exposure increased in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 5. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose of this medicine is contraindicated in some of these patients. Patients taking candesartan cilexetil and rosuvastatin concomitantly may switch to this medicine (a combination product containing the same amounts of each active ingredient) for convenience.
Child dose
Adolescents and children 18 years of age or younger: The safety and efficacy have not been established. Adolescents and children 18 years of age or younger: The safety and efficacy have not been established.

Ingredients

Manufacturer
Dong-A ST Co., Ltd.

Efficacy & effects

Treatment of hypertension and heart failure, improvement of dyslipidemia, and suppression of the progression of atherosclerosis and cardiovascular risk

  • Essential hypertension
  • heart failure
  • left ventricular systolic dysfunction
  • primary hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • mixed hyperlipidemia
  • homozygous familial hypercholesterolemia
  • hypercholesterolemia
  • primary dysbetalipoproteinemia
  • elevated high-sensitivity C-reactive protein
  • hypertension
  • low HDL-cholesterol levels
View approved original text

This medication is prescribed only for patients who need to take Candesartan Cilexetil for the treatment of hypertension and heart failure, combined with Rosuvastatin for managing hypercholesterolemia. Candesartan Cilexetil helps in the treatment of essential hypertension and heart failure with reduced left ventricular function. It can be administered as an additional treatment particularly when ACE inhibitors are not suitable. Rosuvastatin assists dietary management for patients with hypercholesterolemia and hyperlipidemia and is effective in slowing the progression of atherosclerosis. Additionally, it is used for certain familial hypercholesterolemia patients and helps reduce the risk of stroke, myocardial infarction, and revascularization in adults with elevated high-sensitivity C-reactive protein levels who are at risk for cardiovascular disease. This medication is primarily used to treat hypertension, heart failure, and hyperlipidemia.

How to take

Adult dose

This medicine is for use in adults only. The dose should be individualized for each patient based on the efficacy and tolerability of each component, candesartan cilexetil and rosuvastatin. ○ Candesartan cilexetil 1. Essential hypertension 1) Adults: The recommended initial and maintenance dose is 8 ∼ 16 mg of candesartan cilexetil orally once daily. If blood pressure is not adequately controlled after 4 weeks of treatment with 16 mg once daily, the dose may be increased to a maximum of 32 mg once daily. If blood pressure is still not controlled at this dose, other treatments should be considered. The maximum effect is achieved within 4 weeks of starting treatment. 2) Elderly patients: No adjustment of the initial dose is necessary. 3) Patients with intravascular volume depletion: For patients at increased risk of hypotension, such as those with volume depletion, administer an initial dose of 4 mg with careful monitoring. 4) Patients with renal impairment: The initial dose for patients with renal impairment, including those receiving hemodialysis, is 4 mg; adjust the dose according to the patient's response. Experience in patients with severe or end-stage renal impairment (creatinine clearance < 15 mL/min) is limited. 5) Patients with hepatic impairment: The initial dose for patients with mild to moderate hepatic impairment is 2 mg once daily; adjust the dose according to the patient's response. There is no experience in patients with severe hepatic impairment. 2. Heart failure 1) Adults: An initial dose of 4 mg once daily is recommended. The dose may be doubled at intervals of 2 weeks or more, up to a maximum of 32 mg once daily, depending on the patient's tolerability. 2) Elderly patients, patients with intravascular volume depletion, patients with renal impairment, and patients with mild to moderate hepatic impairment: No adjustment of the initial dose is necessary. ○ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, which controls the condition in most patients. The maintenance dose should be appropriately adjusted at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and the patient's response, and may be increased to a maximum of 20 milligrams daily. 2. Elderly patients: No dose adjustment is necessary. 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering this medicine at a dose of 20mg to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but exposure increased in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 5. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose of this medicine is contraindicated in some of these patients. Patients taking candesartan cilexetil and rosuvastatin concomitantly may switch to this medicine (a combination product containing the same amounts of each active ingredient) for convenience.

Child dose

Adolescents and children 18 years of age or younger: The safety and efficacy have not been established. Adolescents and children 18 years of age or younger: The safety and efficacy have not been established.

Precautions

This medication can cause severe damage to the fetus, especially in the second to third trimesters of pregnancy, so it must be discontinued immediately upon confirmation of pregnancy. It should not be used in patients with allergies to this drug or its components, severe liver dysfunction, women who are pregnant or breastfeeding, and those with certain renal diseases, muscle disorders, or hereditary angioedema. Elderly patients, those with compromised liver function, patients with hyperkalemia, and those with heart or kidney diseases should use this medication cautiously, and regular blood tests and monitoring of physical condition during treatment are essential. It may cause muscle pain, muscle weakness, and rarely, severe muscle destruction (rhabdomyolysis); consult a doctor immediately if muscle pain or weakness is experienced. Liver function abnormalities may occur, so liver enzyme levels should be checked before treatment, and liver function tests should be conducted periodically while taking the medication. This drug can interact with several other medications, so patients should inform their doctors or pharmacists if they are taking other drugs, especially potassium-sparing diuretics or certain antibiotics, antifungals, and immunosuppressants. Pregnant or breastfeeding women should not take this medication, and women of childbearing age should use appropriate contraceptive methods. The safety and efficacy of this medication in children have not been established; therefore, it should not be administered. Overdose may result in hypotension, dizziness, rapid heartbeat, etc., and in such cases, seek appropriate medical treatment immediately. Dizziness or fatigue may occur during treatment, so caution is advised when driving or operating machinery. Keep the medication out of the reach of children and store it in its original container to maintain quality.

Side effects

Headache, nasopharyngitis, local infection, fatigue, generalized pruritus, dermatitis, itching, joint stiffness, limb pain, photophobia, dyspepsia, increased blood sugar, decreased serum sodium, hand fracture, hypoglycemia, nephrolithiasis, cough, urticaria, myalgia, myopathy, rhabdomyolysis, asthenia, nausea, constipation, abdominal pain, pancreatitis, rash, arthralgia, low back pain, thrombocytopenia, jaundice, hepatitis, Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome, lupus-like syndrome, muscle rupture, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disturbance, insomnia, nightmares, sexual dysfunction, gynecomastia, fatal and non-fatal hepatic failure, amnesia, peripheral neuropathy, paralysis, tension increase, syncope, facial flushing, weight gain, facial edema, thirst, decreased libido, forgetfulness, appetite loss, increased appetite, tinnitus, taste disorder, erectile dysfunction, dizziness, orthostatic dizziness, chest discomfort, inflammation, sense of foreign body, chalazion, periodontal disease, increased blood pressure, orthostatic hypotension, cerebral infarction, spondyloarthritis, musculoskeletal discomfort, pneumonia, femoral fracture, contusion, unstable angina, idiopathic pulmonary fibrosis, wet cough, worsening hypertension, unstable blood pressure, vertigo, positional vertigo, adrenal insufficiency, intestinal vascular edema, shock, syncope, loss of consciousness, hypotension, blood pressure drop, renal function impairment, hyperkalemia, increased creatine kinase, hyperglycemia, hypertriglyceridemia, hyperuricemia, myalgia, epistaxis, anxiety, somnolence, dyspnea, rash, increased sweating, hematuria, weakness, joint pain, numbness, dysesthesia, generalized pain, muscle cramping, gout

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to protect it from air and moisture. It is best to maintain a room temperature between 1 to 30 degrees Celsius. Proper storage will help preserve the efficacy of the medication for a longer period.

Appearance and packaging

Appearance

Yellow, round film-coated tablets

Package unit

30 tablets (10 tablets/PTP x 3)

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.